Conmed (NYSE: CNMD) reported Q2 EPS of $0.98, $0.07 better than the analyst estimate of $0.91. Revenue for the quarter came in at $332.1 million versus the consensus estimate of $334.34 million.

GUIDANCE:

Conmed sees FY 2024 EPS of $3.95-$4.02, versus the consensus of $4.29. Conmed sees FY 2024 revenue of $1.305-1.315 billion, versus the consensus of $1.34 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.